Novartis AG (NVS) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Novartis AG stock price
Novartis AG latest news:
UPDATE 1-Novartis CAR-T therapy leads to durable response in lymphoma study
Dec 10 (Reuters) - Patients with an advanced form of an
aggressive blood cancer who had initially responded to Novartis'
new type of gene-modifying immunotherapy continued to
respond at least six months after treatment, according to
updated data released at a medical meeting on Sunday.
BRIEF-ACCC Institutes Proceedings Against GSK, Novartis
Australian Competition and Consumer Commission. * INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD AND NOVARTIS CONSUMER HEALTH AUSTRALASIA. * PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.
BRIEF-Advanced Accelerator Applications Board Recommends $3.9 Bln All Cash Tender Offer By Novartis
Advanced Accelerator Applications Sa(AAAP) : * ADVANCED ACCELERATOR APPLICATIONS BOARD OF DIRECTORS RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS. * ADVANCED ACCELERATOR APPLICATIONS (AAAP) - CO'S BOARD RECOMMENDS $3.9 BILLION ALL CASH TENDER OFFER BY NOVARTIS Source text for Eikon: Further company coverage:
Mylan shares jump after report Amazon is in talk with generic drug makers
Shares of drugmaker Mylan NV shot up in the extended session Thursday after a CNBC report that Amazon.com Inc. was holding preliminary talks with generic drugmakers -- including Mylan and Novartis AG unit Sandoz -- as it contemplates entering the pharmacy business. CNBC reported that the talks were high-level, but said Amazon's plans were still not clear. Mylan shares were last up 4.5% after hours, after closing down 0.9%; Novartis shares were up slightly after hours. Speculation about Amazon's entry into the pharmacy business has weighed on pharmaceutical middlemen stocks in recent months. As MarketWatch has reported, Amazon's entry into the field could also have major implications for consumers.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
BRIEF-Novartis announces phase three strive data published in NEJM
Novartis Ag: * NOVARTIS ANNOUNCES PHASE III STRIVE DATA PUBLISHED IN NEJM DEMONSTRATING SIGNIFICANT AND SUSTAINED EFFICACY OF ERENUMAB IN MIGRAINE PREVENTION. * NOVARTIS - NEJM PUBLISHED POSITIVE RESULTS FROM 6-MONTH PHASE III STRIVE STUDY EVALUATING ERENUMAB IN PREVENTION OF EPISODIC MIGRAINE. * - ERENUMAB DELIVERED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCES FR...
Novartis launches heart drug counter-offensive
ZURICH, Nov 13 (Reuters) - Novartis plans to plow
through doubts over its canakinumab drug by asking regulators
this year to approve the medicine as a treatment for a group of
heart attack survivors that the Swiss drugmaker says is most
likely to benefit.
Novartis posts eye drug data amid play for Eylea's turf
Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.
BRIEF-Advanced Accelerator announces $3.9 bln all cash proposed tender offer by Novartis
Advanced Accelerator Applications Sa(AAAP). * Advanced accelerator applications announces $3.9 billion all cash proposed tender offer by Novartis. * Novartis will make cash tender offer to acquire all outstanding shares of co, including ADS, for $41 a share and $82 per ADS. * Deal represents 47 percent premium to 30 volume-weighted trading days prior to unaffected share price on nasdaq on Sept 27.
BRIEF-Ophthotech recieves termination notice from Novartis Pharma
* Ophthotech-On oct 24, co received from Novartis Pharma
notice terminating Licensing & Commercialization Agreement
between parties dated May 19, 2014
Source text : (http://bit.ly/2gPty5O)
Further company coverage:
Novartis boosts third-quarter profit, pushes Alcon decision to 2019
Novartis's third-quarter core net income rose 4 percent at constant currencies, beating expectations.
BRIEF-Novartis CEO: Alcon spinoff 'probably direction we are headed' - CNBC
* Ceo says wants to time alcon exit when market is strong,
expects strong market to continue - cnbc
BRIEF-Novartis CEO: Novartis shareholders would get Alcon shares in listing
* CEO Joe Jimenez says expects U.S. price pressure on
generics business to remain
Novo Nordisk A/SNVO
NQ Mobile Inc.NQ
Nu Skin EnterprisesNUS
Nustar Energy L.P.NS